QLK Completes New Strategic Financing Round Led by Summit Healthcare Investment to Build an Integrated Online Diagnosis and Treatment Ecosystem Linking Doctors, Medicines, and Patients
Recently, according to VCBeat (WeChat ID: vcbeat), it was learned thatQilekang, a comprehensive internet healthcare enterprise, has completed a new round of strategic financing led by GTJA Investment. This marks another financing deal in the internet healthcare sector.
“This collaboration is of significant importance. Beyond providing financial support, GTJA Investment will also lend its resources, expertise, and influence in the healthcare sector. Following this round of financing, 7LeKang will focus on upgrading and iterating its brand, products, and services, continuously expanding the boundaries of ‘Internet Plus’ comprehensive health services, and steadily enhancing its core competitiveness in the internet healthcare field,” said Shi Zhenyang, Founder and Chairman of 7LeKang, highlighting the significance of this partnership.
Founded in Guangzhou in 2010, Seven Luck Kang (Qi Le Kang), a government-authorized medical institution, has built an efficient and trustworthy ecosystem service platform for doctors, patients, hospitals, and pharmaceutical companies through its internet healthcare system, leveraging its leading R&D capabilities in information technology and comprehensive layout across the medical industry. After seven years of development, its business now covers four core segments: internet hospital, mobile health, pharmaceutical e-commerce, and chain pharmacies.
In terms of internet hospitals, as of 2018, Qilekang had become the largest internet hospital in China by prescription volume.Qilekang Internet Hospital boasts a comprehensive data infrastructure, encompassing electronic health record (EHR) systems, electronic medical record (EMR) systems, e-prescribing and online medical order systems, telemedicine platforms, prescription review and medication delivery systems, as well as payment and settlement systems. It provides physicians with a web-based platform for multi-site practice, while promoting the balanced allocation of medical resources through regional healthcare information interoperability, thereby facilitating greater access to high-quality medical care at the primary care level.
In terms of doctor-patient engagement, Qilekang leverages its “Qilekang Doctor” app, which features separate interfaces for physicians and patients. The physician-side product is positioned for the diagnosis and management of chronic diseases, empowering doctors with a suite of services including patient management, doctor-patient communication, electronic cloud-based medical records, post-consultation follow-ups, and medication recommendations, effectively serving as a portable virtual clinic. The user-side interface supports online medical information exchange for hundreds of thousands of users simultaneously, offering a range of medical services such as online consultations, intelligent triage, appointment scheduling, medication counseling, health check-up bookings, prescription inquiries, and payment for diagnostic and treatment services.
In the pharmaceutical sector, Qilekang was among the first enterprises to obtain qualifications for online drug sales. It operates multiple third-party sales platforms as well as its own proprietary platforms, including an official website and mobile applications. The company has independently developed and implemented several advanced systems, such as a Warehouse Management System (WMS), a Supply Chain Management System, an Order Fulfillment Center (OFC) system, and a foundational database management system. These systems enable fully paperless operations and provide comprehensive management of the entire process—from initial vendor qualification approval, goods receipt and inspection, warehousing, and outbound order verification, to pharmaceutical transportation and cold-chain logistics—thereby achieving thorough backend tracking and query capabilities.
Meanwhile, the Qilekang chain pharmacy segment is headquartered in Guangdong and has expanded its footprint across China. By integrating with Qilekang’s internet diagnosis and treatment system and internet hospital network, it has established an efficient and convenient service network. Additionally, it has built the most comprehensive drug database in the industry, containing detailed information on over 30,000 pharmaceutical products, consolidating all data related to drug safety and usage, as well as all information required for Good Supply Practice (GSP) compliance.It is also among the first companies in China to receive approval for establishing pilot pharmaceutical B2C logistics operations. By leveraging electronic drug supervision codes as the core mechanism, it has achieved end-to-end traceability management throughout the drug distribution process, thereby ensuring drug quality and safety during delivery.
Regarding the collaboration with Qilekang, Huang Qing, Executive Vice General Manager and Managing Partner of GTJA Investment Group, stated that innovation is fundamental to the rapid development of the healthcare industry.Entrepreneurs and innovative enterprises are the main drivers of innovation, which also relies on capital support. As a new model of medical and health services, internet hospitals have become one of the key areas of focus for GTJA Capital. GTJA Capital has been seeking management teams with market-oriented and brand-aware mindsets, as well as innovative companies with clear positioning, development goals, and unique business models. In this process, they discovered and gained an in-depth understanding of Qilekang.
“GTJA Capital places special emphasis on growing alongside its portfolio companies. Beyond capital services, we have established professional post-investment, research, and brand teams to provide comprehensive support in strategy, management, industry research, and branding, tailored to the needs of our portfolio companies.”Within the GTJA Capital investment ecosystem, we will spare no effort in building a resource platform for 7LeKang and providing comprehensive post-investment services to accelerate its rapid development.”Huang Qing shared GTJA Investment's post-investment service management system.
Yu Jianlin, Executive Partner of GTJA Investment Group, stated: “As China’s healthcare reform enters its ‘deep-water zone,’ policies are vigorously promoting the ‘Internet + Healthcare’ and ‘Chronic Disease Management + Online Prescription’ models. Meanwhile, the outflow of hospital prescriptions will profoundly reshape the distribution landscape of the pharmaceutical industry, giving rise to new scenarios for medical consultation and drug purchasing.”
As the leading enterprise in fulfilling prescription drug orders for chronic disease follow-up visits, Qilekang focuses its core business on internet hospital services, establishing a complete online healthcare loop integrating “physicians, pharmaceuticals, and patients.” Hundreds of thousands of licensed physicians on its platform have delivered tens of millions of convenient, high-quality, and integrated remote chronic disease management services to millions of patients. After conducting in-depth research and analysis of the current status and development trends of internet hospitals in China, we are more optimistic about Qilekang’s current business model and growth prospects.
Regarding future planning, Shi Zhenyang proposed that the development of Qilekang must adhere to the fundamental principles and rules of medicine. In the future, the company will fully leverage technologies such as big data and artificial intelligence to continue developing and connecting all nodes across the chronic disease management service chain, including physicians, patients, pharmaceutical companies, insurers, and testing institutions. This approach aims to maximize the value delivered by physicians, ensure that patients with chronic diseases receive the most timely and appropriate care, and truly realize the vision of “a world free from disease.”